Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedJun 04, 2026
DataAggregated Company Financials
Companies63
  • 7D6.5%
  • 3M-0.5%
  • 1Y11.9%
  • YTD-14.0%

The Life Sciences industry is up 7.2% in the last week, with Thermo Fisher Scientific up 7.6%. This means that the industry has gained 13% over the past year. As for the next few years, earnings are expected to grow by 17% per annum.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 04 Jun 2026US$583.0bUS$150.6bUS$13.8b37x42.4x3.9x
Sat, 02 May 2026US$551.1bUS$149.1bUS$13.7b36.4x40.1x3.7x
Mon, 30 Mar 2026US$532.8bUS$147.8bUS$14.0b34.8x38x3.6x
Wed, 25 Feb 2026US$593.7bUS$147.7bUS$13.9b34.1x42.7x4x
Fri, 23 Jan 2026US$710.1bUS$145.8bUS$12.4b36.7x57.4x4.9x
Sun, 21 Dec 2025US$651.7bUS$145.8bUS$12.5b34.7x52.2x4.5x
Tue, 18 Nov 2025US$649.0bUS$145.7bUS$12.2b34.1x53.2x4.5x
Thu, 16 Oct 2025US$615.0bUS$144.3bUS$14.6b32.5x42.3x4.3x
Sat, 13 Sep 2025US$580.3bUS$144.3bUS$14.6b28.6x39.9x4x
Mon, 11 Aug 2025US$550.7bUS$144.2bUS$14.4b28.5x38.2x3.8x
Wed, 09 Jul 2025US$537.0bUS$142.9bUS$9.1b36x58.8x3.8x
Fri, 06 Jun 2025US$514.9bUS$142.9bUS$9.2b34.8x56.2x3.6x
Sun, 04 May 2025US$523.7bUS$142.4bUS$9.7b37.8x54.3x3.7x
Tue, 01 Apr 2025US$575.3bUS$142.5bUS$10.0b37.6x57.8x4x
Thu, 27 Feb 2025US$619.3bUS$143.3bUS$9.8b38.4x63.4x4.3x
Sat, 25 Jan 2025US$702.6bUS$142.4bUS$10.2b45.1x68.8x4.9x
Mon, 23 Dec 2024US$652.4bUS$142.4bUS$10.2b44.3x63.8x4.6x
Wed, 20 Nov 2024US$630.4bUS$142.4bUS$10.4b41.6x60.8x4.4x
Fri, 18 Oct 2024US$725.2bUS$141.8bUS$8.5b37.1x85.4x5.1x
Sun, 15 Sep 2024US$740.7bUS$141.8bUS$8.5b37.5x87.2x5.2x
Tue, 13 Aug 2024US$727.5bUS$141.5bUS$8.5b38.5x85.8x5.1x
Thu, 11 Jul 2024US$662.3bUS$141.3bUS$12.2b39.8x54.4x4.7x
Sat, 08 Jun 2024US$718.4bUS$141.3bUS$12.2b37.7x59x5.1x
Mon, 06 May 2024US$711.4bUS$141.7bUS$12.5b38.9x56.9x5x
Wed, 03 Apr 2024US$737.7bUS$142.0bUS$12.8b43.4x57.7x5.2x
Fri, 01 Mar 2024US$739.0bUS$142.2bUS$12.7b43.8x58x5.2x
Sun, 28 Jan 2024US$698.4bUS$153.8bUS$14.2b35.5x49.3x4.5x
Tue, 26 Dec 2023US$698.8bUS$153.8bUS$14.2b37.5x49.1x4.5x
Thu, 23 Nov 2023US$616.3bUS$153.8bUS$14.0b33.5x44x4x
Sat, 21 Oct 2023US$607.7bUS$154.6bUS$11.2b31.3x54.2x3.9x
Mon, 18 Sep 2023US$697.4bUS$154.6bUS$11.2b33.4x62.2x4.5x
Wed, 16 Aug 2023US$719.3bUS$154.7bUS$11.4b32.4x62.9x4.7x
Fri, 14 Jul 2023US$704.1bUS$155.5bUS$12.7b29.1x55.5x4.5x
Sun, 11 Jun 2023US$680.2bUS$152.4bUS$12.5b29.1x54.4x4.5x
Price to Earnings Ratio

54.4x


Total Market Cap: US$680.2bTotal Earnings: US$12.5bTotal Revenue: US$152.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 56.4x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 43.2x which is lower than its 3-year average PE of 56.4x.
  • The 3-year average PS ratio of 4.4x is higher than the industry's current PS ratio of 3.9x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 3.2% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.35%
Healthcare-1.17%
Life Sciences6.46%
Clinical Research and Equipment6.46%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
TMO Thermo Fisher ScientificUS$473.953.9%
+US$6.6b		17.4%PE25.7x
A Agilent TechnologiesUS$137.4018.6%
+US$6.1b		19.5%PE27.4x
WAT WatersUS$379.7711.0%
+US$3.7b		7.5%PE82.9x
DHR DanaherUS$178.082.9%
+US$3.5b		-7.8%PE34.3x
ILMN IlluminaUS$170.9313.8%
+US$3.1b		105.5%PE30.3x

Latest News

NOTV
US$0.12
Inotiv
7D
-55.2%
1Y
-96.0%
A
US$137.40
Agilent Technologies
7D
18.6%
1Y
19.5%
WAT
US$379.77
Waters
7D
11.0%
1Y
7.5%
TMO
US$473.95
Thermo Fisher Scientific
7D
3.9%
1Y
17.4%
BRKR
US$62.70
Bruker
7D
29.0%
1Y
65.7%
ICLR
US$143.90
ICON
7D
21.5%
1Y
3.1%
Narrative Update • Jun 03

ICLR: Accounting Headwinds And 2026 Margin Pressure Will Restrain Earnings Quality

Analysts have lifted the ICON fair value estimate from $75.00 to $125.00, reflecting a reset after the accounting investigation, stronger reported bookings momentum, and updated assumptions for revenue growth, profit margins, and future P/E multiples in line with the recent wave of higher Street price targets. Analyst Commentary Street research around ICON has turned more constructive on the fair value range after the accounting investigation update, but opinions are still split on how much risk remains in the story.
DHR
US$178.08
Danaher
7D
2.9%
1Y
-7.8%
OABI
US$2.50
OmniAb
7D
-3.5%
1Y
78.6%
Narrative Update • Jun 01

OABI: 2026 Revenue Guidance Will Shape Long Term Upside Potential

Analysts have nudged their price target on OmniAb slightly higher to $7.33, reflecting updated assumptions around the company’s discount rate, long term revenue growth, profit margin, and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, projecting revenue in a range of $25 million to $30 million.
SHC
US$15.27
Sotera Health
7D
-1.7%
1Y
23.5%
ILMN
US$170.93
Illumina
7D
13.8%
1Y
105.5%
Narrative Update • Jun 01

ILMN: Clinical Momentum And Softer Competition Will Shape A Balanced Outlook

Analysts have lifted the fair value estimate for Illumina from $156.51 to $175.00, citing Street research that points to building clinical momentum, easing competitive concerns, and a series of higher price targets from several firms. Analyst Commentary Recent Street research on Illumina has tilted more constructive, with several bullish analysts pointing to improving clinical traction and a less intense competitive backdrop as key supports for the stock.
IQV
US$182.05
IQVIA Holdings
7D
9.9%
1Y
23.1%
Narrative Update • May 31

IQV: Future Returns Will Depend On AI Trial Expansion And Execution Risk Balancing

Narrative Update on IQVIA Holdings The analyst price target for IQVIA Holdings has moved from $186.12 to $195.00, reflecting updated assumptions on discount rate, profit margin, and P/E, alongside recent research in which several firms reiterated constructive views on clinical trial activity, AI related cost savings, and the stock's valuation. Analyst Commentary Recent Street research on IQVIA Holdings has been mixed, with some bullish rating changes and initiations sitting alongside lower price targets from more cautious voices.
CDT
US$0.81
CDT Equity
7D
-26.8%
1Y
-99.8%
SEER
US$1.86
Seer
7D
-1.6%
1Y
-15.1%
BIO
US$304.83
Bio-Rad Laboratories
7D
-0.2%
1Y
37.3%
ATLN
US$1.33
Atlantic International
7D
-4.3%
1Y
-45.0%
CSBR
US$5.69
Champions Oncology
7D
-3.1%
1Y
-10.8%